Thirty states have drafted more than 60 drug price transparency bills aimed at identifying drug maker expenses and unveiling business practices of pharmacy benefit managers, according to an analysis by the National Academy for State Health Policy. Most of the action to stem prescription drug price increases is taking place in the states, which are dealing with strained budgets. Avalere Health reported in May on the uptick . At the time, the group said 17 states, plus Puerto Rico, were...